Search results

  1. INCMOR0208-301 (LYTMOR0208)

    … in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Drug Name …

  2. OZM-109 (LYTOZM109)

    … R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma Cancer Type …

  3. GO29781 (LYT29781)

    … Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia …

  4. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based..

    … Journal Leuk Lymphoma, 2024 Authors …

  5. Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.

    … Analysis. Journal Clin Lymphoma Myeloma Leuk. 2025 …

  6. (Acerta) ACE-LY-308

    … (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma Cancer Type …

  7. CCTG opens its first two investigator-led cell therapy trials in Canada

    … before and after CAR-T treatment for relapsed mantle cell lymphoma (IND245) and a novel Canadian-developed CAR T-cell …

    Jul 9, 2026

  8. LY.18 (LYLY18)

    … for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Cancer Type …

  9. MSK 16-1536 (LYT209447)

    … and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma Cancer Type …

  10. Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.

    … Use in Canada. Journal Clin Lymphoma Myeloma Leuk 2025 …

Back to top